Floatz logo

Therapeutic Asset Ratings

435 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Trastuzumab Emtansine
Malignant Pancreatic Neoplasm
OHSU Knight Cancer InstituteP2B (63)
Vinorelbine
Advanced Malignant Solid Neoplasm
OHSU Knight Cancer InstituteP2B (63)
Olanzapine
Advanced Malignant Solid Neoplasm
OHSU Knight Cancer InstituteP3B (62)
Blinatumomab
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
OHSU Knight Cancer InstituteP2B (62)
Entrectinib
Anatomic Stage IV Breast Cancer AJCC v8
OHSU Knight Cancer InstituteP2B (62)
Ipilimumab
Acute Myeloid Leukemia
OHSU Knight Cancer InstituteP2B (62)
Irinotecan
Myelodysplastic Syndrome
OHSU Knight Cancer InstituteP2B (62)
Letrozole
Advanced Malignant Solid Neoplasm
OHSU Knight Cancer InstituteP2B (62)
METHOTREXATE
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
OHSU Knight Cancer InstituteP2B (62)
Pembrolizumab
Prostate Carcinoma
OHSU Knight Cancer InstituteP2B (62)
TRASTUZUMAB
Advanced Malignant Solid Neoplasm
OHSU Knight Cancer InstituteP2B (62)
TRASTUZUMAB
Recurrent Ovarian Carcinoma
OHSU Knight Cancer InstituteP2B (62)
Trastuzumab Emtansine
Advanced Malignant Solid Neoplasm
OHSU Knight Cancer InstituteP2B (62)
Vorinostat
Chronic Myeloid Leukemia
OHSU Knight Cancer InstituteP2B (62)
Atezolizumab
Ovarian Cancer
OHSU Knight Cancer InstituteP3B (61)
Copanlisib
Non-Hodgkin Lymphoma
OHSU Knight Cancer InstituteP3B (61)
Arimidex
Recurrent Ovarian Carcinoma
OHSU Knight Cancer InstituteP2B (61)
Durvalumab
Prostate Cancer
OHSU Knight Cancer InstituteP2B (61)
Epirubicin
Prostate Adenocarcinoma
OHSU Knight Cancer InstituteP2B (61)
gsk1120212
Recurrent Breast Carcinoma
OHSU Knight Cancer InstituteP2B (61)
Inno-206
Chronic Myeloid Leukemia
OHSU Knight Cancer InstituteP2B (61)
Pembrolizumab
Prostate Adenocarcinoma
OHSU Knight Cancer InstituteP2B (61)
su011248
Refractory Multiple Myeloma
OHSU Knight Cancer InstituteP2B (61)
Vinorelbine
Metastatic Pancreatic Adenocarcinoma
OHSU Knight Cancer InstituteP2B (61)
Irinotecan
Blastic Phase Chronic Myelogenous Leukemia
OHSU Knight Cancer InstituteP1/2B (61)
Showing 76 to 100 of 435 assets
PreviousPage 4 of 18Next